. 2012 Oct 8;8(5):767–775. doi: 10.5114/aoms.2012.31610

Table III.

Efficacy and safety meta-analysis and single study results for sipuleucel-T compared to placebo for castration-resistant prostate cancer

Parameter	References	Results	Value of p
Overall survival	Meta-analysis (D9901 [21], D9902A [25], IMPACT [26])	HR = 0.73 (95% CI: 0.61-0.88)	0.001
Time to progression	Meta-analysis (D9901 [21], D9902A [25], IMPACT [26])	HR = 0.89 (95% CI: 0.75-1.05)	0.17
Serum PSA level reduction of at least 50%	IMPACT [26]	RB = 1.97 (95% CI: 0.48-8.14)	0.38
All adverse events	Meta-analysis (D9901 [21], D9902A [25], IMPACT [26])	RR = 1.03 (95% CI: 1.00-1.05)	0.06
Adverse events grades 3 to 5	Meta-analysis (D9901 [21], D9902A [25], IMPACT [26])	RR = 0.98 (95% CI: 0.79-1.22)	0.86
Cerebrovascular events	Meta-analysis (D9901 and D9902A [25], IMPACT [26])	RR = 1.93 (95% CI: 0.73-5.09)	0.18